These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 16368516)

  • 21. Role of matrix metalloproteinases in delayed cortical responses after stroke.
    Zhao BQ; Wang S; Kim HY; Storrie H; Rosen BR; Mooney DJ; Wang X; Lo EH
    Nat Med; 2006 Apr; 12(4):441-5. PubMed ID: 16565723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Role of matrix metalloproteinases in the pathogenesis of multiple sclerosis].
    Kurzepa J; Bartosik-Psujek H; Suchozebrska-Jesionek D; Rejdak K; Stryjecka-Zimmer M; Stelmasiak Z
    Neurol Neurochir Pol; 2005; 39(1):63-7. PubMed ID: 15735992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extracellular matrix degradation by metalloproteinases and central nervous system diseases.
    Lukes A; Mun-Bryce S; Lukes M; Rosenberg GA
    Mol Neurobiol; 1999 Jun; 19(3):267-84. PubMed ID: 10495107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Matrix metaloproteinases in neurological brain lesions: a new therapeutic target?].
    Vilalta A; Sahuquillo Barris J; Poca MA
    Rev Neurol; 2010 Jul; 51(2):95-107. PubMed ID: 20602315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ischemic-Reperfusion Injury Increases Matrix Metalloproteinases and Tissue Metalloproteinase Inhibitors in Fetal Sheep Brain.
    Chen X; Patra A; Sadowska GB; Stonestreet BS
    Dev Neurosci; 2018; 40(3):234-245. PubMed ID: 30048980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Update on the Role of Matrix Metalloproteinases in the Pathogenesis of Multiple Sclerosis.
    Boziki M; Grigoriadis N
    Med Chem; 2018 Feb; 14(2):155-169. PubMed ID: 28875862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early upregulation of matrix metalloproteinases following reperfusion triggers neuroinflammatory mediators in brain ischemia in rat.
    Amantea D; Russo R; Gliozzi M; Fratto V; Berliocchi L; Bagetta G; Bernardi G; Corasaniti MT
    Int Rev Neurobiol; 2007; 82():149-69. PubMed ID: 17678960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Matrix Metalloproteinases, Neural Extracellular Matrix, and Central Nervous System Pathology.
    De Luca C; Papa M
    Prog Mol Biol Transl Sci; 2017; 148():167-202. PubMed ID: 28662822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Extracellular matrix -- from basic research to clinical significance. An overview with special consideration of matrix metalloproteinases].
    Hamacher S; Matern S; Roeb E
    Dtsch Med Wochenschr; 2004 Sep; 129(38):1976-80. PubMed ID: 15375740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects.
    Levin M; Udi Y; Solomonov I; Sagi I
    Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt A):1927-1939. PubMed ID: 28636874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Matrix metalloproteinases in liver injury, repair and fibrosis.
    Duarte S; Baber J; Fujii T; Coito AJ
    Matrix Biol; 2015; 44-46():147-56. PubMed ID: 25599939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implication of matrix metalloproteinases in regulating neuronal disorder.
    Mukherjee A; Swarnakar S
    Mol Biol Rep; 2015 Jan; 42(1):1-11. PubMed ID: 25374425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures.
    Rosenberg GA; Cunningham LA; Wallace J; Alexander S; Estrada EY; Grossetete M; Razhagi A; Miller K; Gearing A
    Brain Res; 2001 Mar; 893(1-2):104-12. PubMed ID: 11222998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Downregulation of membrane type-matrix metalloproteinases in the inflamed or injured central nervous system.
    Toft-Hansen H; Babcock AA; Millward JM; Owens T
    J Neuroinflammation; 2007 Sep; 4():24. PubMed ID: 17883829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia.
    Gasche Y; Copin JC; Sugawara T; Fujimura M; Chan PH
    J Cereb Blood Flow Metab; 2001 Dec; 21(12):1393-400. PubMed ID: 11740200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke.
    Lopes Pinheiro MA; Kooij G; Mizee MR; Kamermans A; Enzmann G; Lyck R; Schwaninger M; Engelhardt B; de Vries HE
    Biochim Biophys Acta; 2016 Mar; 1862(3):461-71. PubMed ID: 26527183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MMPs in the central nervous system: where the good guys go bad.
    Agrawal SM; Lau L; Yong VW
    Semin Cell Dev Biol; 2008 Feb; 19(1):42-51. PubMed ID: 17646116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MMPs: a novel drug target for schizophrenia.
    Chopra K; Baveja A; Kuhad A
    Expert Opin Ther Targets; 2015 Jan; 19(1):77-85. PubMed ID: 25214056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Matrix metalloproteinases: potential therapeutic target for diabetic neuropathic pain.
    Kuhad A; Singh P; Chopra K
    Expert Opin Ther Targets; 2015 Feb; 19(2):177-85. PubMed ID: 25243524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiphasic roles for matrix metalloproteinases after stroke.
    Rosell A; Lo EH
    Curr Opin Pharmacol; 2008 Feb; 8(1):82-9. PubMed ID: 18226583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.